While semaglutide alone rarely causes hypoglycemia, an overdose can push blood sugar dangerously low, especially if combined with other diabetes medications
Compounded semaglutide has a significantly shorter usable life than brand-name alternatives
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, was selected as an active-comparator placebo proxy because it was recommended in clinical guidelines as a second-line glucose-lowering therapy, had a similar high cost to the study drugs, showed no effect on cardiovascular outcomes in a large randomized controlled trial and has been validated as a placebo proxy in prior claims-based research 20,41
The robust and predictable PK profile across diverse patient populations means that no dose adjustments are required for patients based on these common factors
the brand's Privacy Policy references Manifest Pharmacy administratively, though the reviewed materials don't confirm it as every patient's exclusive dispensing pharmacy